CD93 and systemic lupus erythematosus: In summary, the data reviewed in this article supports the idea that the C1q/C1qR system is an ideal molecular target for the design of antibody- or peptide-based therapy to attenuate acute and chronic inflammation associated with autoimmune diseases, SLE in particular.